Search

Your search keyword '"M. Lario"' showing total 10 results
Start Over Author "M. Lario" Topic business
10 results on '"M. Lario"'

1. 125P Benefit of immunotherapy in advanced NSCLC patients selected by KRAS mutations: A single institute retrospective analysis

Author

Y. Lage, L. Sanz Gómez, E.M. Vida Navas, J.J. Soto Castillo, E. Corral de la Fuente, M.E. Olmedo García, A. Gómez Rueda, M. Lario, and P. Garrido Lopez

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Internal medicine, Retrospective analysis, Medicine, KRAS, Immunotherapy, business, medicine.disease_cause
Published
2021

2. 52P Genetic and clinical profiling of a cohort of extended small cell lung carcinoma

Author

M.E. Olmedo García, J.J. Soto Castillo, Y. Lage, V. Albarrán Fernández, M. San Román Gil, P. Álvarez Ballesteros, J. Pozas Pérez, J. Esteban Villarrubia, M. Lario, L. Sanz Gómez, A. Caminoa Lizarralde, J. Chamorro Pérez, E.M. Vida Navas, P. Garrido Lopez, J. Torres Jiménez, D.I. Rosero Rodríguez, E. Corral de la Fuente, and A. Gómez Rueda

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, Cohort, medicine, Profiling (information science), Small Cell Lung Carcinoma, business
Published
2021

3. 6P Clinical and molecular characteristics in non-small cell lung cancer patients with alteration in PIK3 pathway

Author

A. Gómez Rueda, M.E. Olmedo García, M. Lario, A. Benito Berlinches, P. Álvarez Ballesteros, E. Corral de la Fuente, Y. Lage, A. Santón, J.J. Soto Castillo, J. Torres Jiménez, P. Garrido Lopez, and E.M. Vida Navas

Subjects
Pulmonary and Respiratory Medicine, Oncology, business.industry, Cancer research, medicine, Non small cell, Lung cancer, medicine.disease, business
Published
2021

4. 218P Clinical characteristics and treatment outcomes in lung cancer patients with FGFR genes alterations

Author

A. Benito Berlinches, P. Garrido Lopez, P. Álvarez Ballesteros, M. Lario, J. Torres Jiménez, Y. Lage, M. San Román Gil, J. Esteban Villarrubia, D.I. Rosero Rodríguez, J. Chamorro Pérez, J. Pozas Pérez, V. Albarrán Fernández, L. Sanz Gómez, A. Santón, J.J. Soto Castillo, I. Orejana Martin, E.M. Vida Navas, A. Gómez Rueda, E. Corral de la Fuente, and M.E. Olmedo García

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Fibroblast growth factor receptor, business.industry, Internal medicine, Treatment outcome, medicine, Lung cancer, medicine.disease, business, Gene
Published
2021

5. 124P KRAS mutated (mt) non-small cell lung cancer (NSCLC) and response to antiPD-1/PD-L1 regarding co-mutational status and assessment of KRAS mutation on plasma or tissue biopsy

Author

A. Benito Berlinches, P. Álvarez Ballesteros, E.M. Vida Navas, Y. Lage, M.E. Olmedo García, J.J. Soto Castillo, E. Corral de la Fuente, A. Gómez Rueda, M. Lario, J. Torres Jiménez, and P. Garrido Lopez

Subjects
Pulmonary and Respiratory Medicine, biology, business.industry, non-small cell lung cancer (NSCLC), medicine.disease, medicine.disease_cause, Oncology, PD-L1, medicine, biology.protein, Cancer research, Mutational status, KRAS, business, Kras mutation, Tissue biopsy
Published
2021

6. Intestinal inflammation worsens epithelial barrier function in rats with cirrhosis and ascites: role of commensal gut flora

Author

A.M. Sánchez-Díaz, R. del Campo, Óscar Pastor, M. Lario, David Díaz, L. Paule, Macarena Rodríguez-Serrano, Agustín Albillos, Melchor Alvarez-Mon, Leticia Muñoz, Eulogio Conde, M.J. Borrero, M. Ubeda, and Laura García-Bermejo

Subjects
Cirrhosis, Hepatology, biology, business.industry, Gut flora, biology.organism_classification, medicine.disease, Intestinal inflammation, Ascites, Immunology, medicine, Epithelial barrier function, medicine.symptom, business
Published
2017

7. The biological response modifier AM3 attenuates the inflammatory cell response and hepatic fibrosis in rats with biliary cirrhosis

Author

Ignacio Blanco, Benito Fraile, Agustín Albillos, Lourdes Lledó, Melchor Alvarez-Mon, Jorge Monserrat, Mónica Nieto, M. Ubeda, Clara Salas, Leticia Muñoz, Ramon Bataller, Óscar Pastor, Eduardo Reyes, and M. Lario

Subjects
Calcium Phosphates, Male, medicine.medical_specialty, Cirrhosis, Biliary cirrhosis, Portal venous pressure, Drug Evaluation, Preclinical, Liver Cirrhosis, Experimental, Monocytes, Immunophenotyping, Immunomodulation, Immune system, Adjuvants, Immunologic, T-Lymphocyte Subsets, Internal medicine, Medicine, Animals, Rats, Wistar, business.industry, Liver Cirrhosis, Biliary, Gastroenterology, Glycopeptides, medicine.disease, Rats, Killer Cells, Natural, Interleukin 10, Endocrinology, Liver, Immunology, Portal hypertension, Cytokines, Tumor necrosis factor alpha, business, Hepatic fibrosis
Abstract

Background An inflammatory immune system response ensues in the liver and in the systemic circulation in cirrhosis, where it contributes to hepatic fibrosis and peripheral vasodilation. Modulation of the inflammatory response without increasing susceptibility to infection is a therapeutic target in cirrhosis. AM3 is a low-toxicity biological response modifier with regulatory effects on innate and adaptative immunity, and the ability to normalise the production of tumour necrosis factor α (TNFα). Aims This was an experimental study to investigate the effects of oral AM3 on the systemic and hepatic inflammatory response, liver fibrosis and on the haemodynamic abnormalities of portal hypertension in rats with biliary cirrhosis. Design Bile-duct ligated rats received a 3-week oral course of AM3 or placebo. Results In cirrhotic rats, AM3 blunted the inflammatory switch of circulating and intrahepatic monocytes and T-cells to TNFα and interferon γ (IFNγ) production, respectively. AM3 modified the intrahepatic polarisation pattern of the regulatory cytokines, decreasing the mRNA expression of transforming growth factor β1 (TGFβ1), interleukin 4 (IL4), and IFNγ, and increasing that of IL10. Total and IFNγ-producing natural killer (NK) cells were lowered by AM3 in the peripheral blood and liver of cirrhotic rats. The immunomodulatory effects of AM3 led to reduced hepatic fibrogenesis in cirrhotic rats, as shown by decreased area of liver fibrosis, hydroxyproline content and mRNA expression of procollagen α1(I). Besides, AM3 lowered portal pressure and systemic hyperaemia. Conclusions The biological response modifier AM3 reverses the concurrent inflammatory immune system activation in peripheral blood and liver of experimental established cirrhosis, which results in reductions of hepatic fibrosis, portal pressure and peripheral vasodilation.

Published
2010

8. 500 THE BIOLOGICAL RESPONSE MODIFIER AM3 ATTENUATES THE LIVER AND PERIPHERAL BLOOD INFLAMMATORY IMMUNE SYSTEM ACTIVATION AND REDUCES HEPATIC FIBROSIS IN RATS WITH BILIARY CIRRHOSIS

Author

Mónica Nieto, Melchor Alvarez-Mon, Eduardo Reyes, M. Lario, Clara Salas, Agustín Albillos, M. Ubeda, Ramon Bataller, L. Muñnoz, I. Blanco, J. Monserrat, Lourdes Lledó, and B. Fraile

Subjects
medicine.medical_specialty, Immune system, Hepatology, business.industry, Internal medicine, Biliary cirrhosis, medicine, Hepatic fibrosis, business, Gastroenterology, Peripheral blood
Published
2010

Catalog

Books, media, physical & digital resources
See catalog results